CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

E-mail : concorddrugsltd@gmail.com Ph.No : +91 9052779505 Website : www.concorddrugs.in

Date: 12.11.2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400001.

Scrip Code: 538965

Sub: Outcome of Board Meeting held on 12.11.2026 pursuant to Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company was held on Thursday, 12th November 2026, wherein the Board inter alia:

1. Considered and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and Half year ended 30th Sep, 2026.
2. The Board took note of the Limited Review Report issued by the Statutory Auditors of the Company on the aforesaid financial results.

Further, the financial results are also available on the website of the Company at Concord Drugs Limited > Investor Relations and on the website of BSE Limited.

The financial results will also be published in the newspapers as per the requirements and in the format prescribed under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 04:00 PM and concluded at 06:30 PM.

This is for your information and records.

Thanking you,
Yours faithfully,
For Concord Drugs Limited

SEELAM MANOJ KUMAR REDDY

Digitally signed by SEELAM MANOJ KUMAR REDDY
DN: c=IN, postalCode=500074, st=TELANGANA, street=HYDERABAD, l=HYDERABAD, o=Personal, serialNumber=ffe63add5ab29a284791a6ab2f02c52247a21830cec0e83106266fa506cff14, pseudonym=2032dc3a6564695ffb3bdc26b372464f25.4.20=b41047200b7834284ea49bc302c859c68a87b1af90add0792da2a09c6b99afa96, email=MANOJREDDY36@GMAIL.COM, cn=SEELAM MANOJ KUMAR REDDY
Date: 2026.11.12 18:44:46 +05'30'

Seelam Manoj Kumar Reddy
Whole Time Director
DIN: 06991382

Concord Drugs Limited

Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

Statement of assets and Liabilities un audited (standalone and Consolidated) for the Six months ended 30.09.2026

Rs in lakhs

		Standalone		Consolidated	
Particulars	**Note**	**30-Sep-26**	**31-Mar-26**	**30-Sep-26**	**31-Mar-26**
ASSETS					
Non-current assets					
(a) Property, plant and equipment	3	1,039.12	1,091.02	1,041.53	1,093.77
(b) Capital Work-in Progress	3	269.49	243.11	269.49	243.11
(c) Investment property	3	63.95	63.95	63.95	63.95
(d) Goodwill	4		-		-
Financial assets		-			
(a) Investments	4	161.50	**161.50**	77.91	78.25
(b) Loans & Advances	4	110.44	7.89	110.44	7.89
Other Non current assets	5	715.21	670.63	715.21	670.63
Total Non - Current Assets		**2,359.71**	**2,238.10**	**2,278.52**	**2,157.61**
Current Assets					
Inventories	7	1,717.29	1,834.99	2,441.65	2,551.60
Financial assets		-			
(a) Investments		-			
(b) Trade receivables	6	4,432.29	2,812.88	4,007.01	2,438.15
(c) Cash and cash equivalents	8	27.18	27.10	29.03	27.81
(d) Bank balances other than (c) above	8	45.93	47.24	45.93	47.24
(e) Other Current Financial Assets	9	34.87	3.77	34.87	3.77
Other current assets	10	813.55	221.41	856.04	262.59
Total Current assets		**7,071.11**	**4,947.38**	**7,414.53**	**5,331.16**
Total Assets		**9,430.82**	**7,185.48**	**9,693.05**	**7,488.76**
EQUITY AND LIABILITIES					
Equity					
Equity share capital	11	1,317.50	1,317.50	1,317.50	1,317.50
Other equity	12	3,754.68	3,533.89	3,754.68	3,533.89
Total Equity		**5,072.18**	**4,851.39**	**5,072.18**	**4,851.39**
Non-current liabilities					
Financial Liabilities					
(a) Borrowings	13	500.90	180.59	500.90	180.59
(b) Trade payables		16.04	15.73	16.04	15.73
Deferred tax liabilities, net	14	61.76	63.50	60.71	62.40
Provisions	15	271.88	271.88	271.88	271.88
Government Grants	13	-	-		
Total Non-current liabilities		**850.59**	**531.69**	**849.53**	**530.60**
Current liabilities					
Financial liabilities					
(a) Borrowings	16	1,533.78	980.45	1,728.59	1,179.33
(b) Trade payables	17	1,781.79	602.49	1,849.30	707.10
(c) Other Current financial liabilities	18	-	90.88	-	90.88
Current tax liabilities, net	15	126.94	41.34	126.94	41.34
Other current liabilities	19	65.55	87.24	66.52	88.13
Total Current liabilities		**3,508.05**	**1,802.40**	**3,771.34**	**2,106.78**
Total liabilities		**4,358.64**	**2,334.09**	**4,620.87**	**2,637.37**
Total Equity and liabilities		**9,430.82**	**7,185.48**	**9,693.05**	**7,488.76**

Concord Drugs Limited * Hyderabad *

By Order of the Board
For Concord Drugs Limited

S. Nagi Reddy

Nagi Reddy Seelam
Managing Director
DIN:01764665

Place:Hyderabad
Date:12.11.2026

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Un Audited Statement Of (standalone and Consolidated) Profit and Loss for the Six months Ended 30.09.2026 Amount in Lakhs

	Particulars	Note	Standalone		Consolidated	
			30-Sep-26	31-Mar-26	30-Sep-26	31-Mar-26
I	**Revenue from Operations**					
	a. Net sales from Operations	20	4,157.79	7,584.86	4,169.21	7,873.68
II	**Other Income**	21	6.43	3.44	6.43	3.44
III	**Total Revenue (I+II)**		**4,164.23**	**7,588.30**	**4,175.65**	**7,877.13**
IV	**Expenses**					
	a.Cost of Material Consumed	22	3,356.86	6,344.53	3,356.09	6,700.61
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-25.52	169.30	-25.52	63.98
	c. Employees Benefit Expenses	24	280.21	489.91	281.85	497.05
	d. Finance Costs	25	86.62	145.91	95.28	171.37
	e. Depreciation and Amortisation expense	3	70.36	135.72	70.71	136.67
	f. Other expenses	26	91.05	158.07	92.13	160.13
	Total Expenses		**3,859.57**	**7,443.44**	**3,870.53**	**7,729.81**
V	**Profit/ (Loss) before Exceptional item and tax (III-IV)**		**304.65**	**144.86**	**305.12**	**147.32**
VI	**Exceptional Items**		-	-	-	
VII	**Profit/ (Loss) before tax (V+VI)**		**304.65**	**144.86**	**305.12**	**147.32**
VIII	**Tax Expense:**		**83.86**	**41.12**	**83.98**	**41.82**
	a. Current tax		85.60	41.34	85.67	41.98
	b. Deferred tax charge/credit		-1.74	-0.22	-1.69	-0.16
IX	**Profit/ (Loss) for the period (VII-VIII)**		**220.79**	**103.74**	**221.14**	**105.50**
X	**Other Comprehensive Income**		-	-	-	-
	Items that will not be reclassified to profit or loss		-	-	-	
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		**220.79**	**103.74**	**221.14**	**105.50**
XI	**Paid-up equity share capital**		**1,317.50**	**1,317.50**	**1,317.50**	1,317.50
	(Face value of the share- Rs. 10 each)					
XII	**Earnings per share (of Rs. 10 each)**					
XIII	a. Basic (in Rs)		1.98	0.93	1.98	0.95
	b. Diluted (in Rs)		1.98	0.93	1.98	0.95

Concord Drugs Limited * Hyderabad *

By Order of the Board
For Concord Drugs Limited

S. Nagi Reddy

Nagi Reddy Seelam
Managing Director
DIN:01764665

Place:Hyderabad
Date:12.11.2026

Concord Drugs Limited
Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

STATEMENT OF Un-AUDITED STANDALONE FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30.09.2026

[Rs. in Lakhs]

Particulars		Quarterly ended			Half Year ended		Year Ended
		30-Sep-26 (Un Audited)	30-Jun-26 (Un Audited)	30-Sep-25 (Audited)	30-Sep-26	30-Sep-25 (Un Audited)	31-Mar-26 (Audited)
I	**Revenue from Operations**						
	a. Net sales from Operations	2,068.93	2,088.86	1,007.28	4,157.79	2,345.63	7,584.86
	b. Other Operating Income	5.61	0.82	0.24	6.43	0.24	3.44
II	**Other Income**						
III	**Total Revenue (I+II)**	**2,074.55**	**2,089.68**	**1,007.52**	**4,164.23**	**2,345.87**	**7,588.30**
IV	**Expenses**						
	a.Cost of Material Consumed	1,703.37	1,653.49	766.89	3,356.86	1,835.81	6,344.53
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-64.50	38.98	-4.51	-25.52	56.13	169.30
	c. Employees Benefit Expenses	155.64	124.57	108.00	280.21	195.11	489.91
	d. Finance Costs	51.51	35.11	39.87	86.62	81.85	145.91
	e. Depreciation and Amortisation expense	35.60	34.76	33.70	70.36	70.24	135.72
	f. Other expenses	42.53	48.52	36.67	91.05	64.61	158.07
	Total Expenses	**1,924.14**	**1,935.43**	**980.62**	**3,859.57**	**2,303.75**	**7,443.44**
	Profit/ (Loss) before Exceptional item and tax (III-IV)	**150.40**	**154.25**	**26.90**	**304.65**	**42.12**	**144.86**
V	**Exceptional Items**	-	-	-		-	-
VI	**Profit/ (Loss) before tax (V-VI)**	150.40	154.25	26.90	304.65	42.12	144.86
VII	**Tax Expense:**	**40.83**	**43.03**	**7.52**	**83.86**	**11.58**	**41.12**
VIII	a. Current tax	41.49	44.11	7.80	85.60	12.95	41.34
0	b. Deferred tax charge/credit	-0.66	-1.08	-0.28	-1.74	-1.37	-0.22
IX	**Profit/ (Loss) for the period (VII-VIII)**	**109.57**	**111.22**	**19.38**	**220.79**	**30.54**	**103.74**
X	**Other Comprehensive Income**	-		-		-	-
	Items that will not be reclassified to profit or loss	-		-		-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	109.57	111.22	19.38	220.79	30.54	103.74
XI	**Paid up Capital**	1,317.50	1,317.50	1,000.00	1,317.50	1,000.00	1,317.50
	(Face value of the share- Rs. 10 each)						
	Other Equity	3,754.68	3,645.12	2,441.89	3,754.68	2,441.89	3,533.89
XII	**Earnings per share (of Rs. 10 each) (in Rupees)**						
XIII	a. Basic (in Rs)	0.83	0.84	0.19	1.68	0.31	0.93
	b. Diluted (in Rs)	0.83	0.84	0.19	1.68	0.31	0.93

Notes:

1	The finnacial results of the company hav been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above standalone financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 12.11.2026
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The Earnings Per Share (EPS) for the quarter ended is not strictly comparable on a Quarter-on-Quarter (QoQ) and Year-on-Year (YoY) basis, as the weighted average number of equity shares outstanding increased during quarter ended 31.03.2026 pursuant to the allotment of 31,75,000 equity shares at ₹36.50 per share through a preferential issue. Notwithstanding the increase of over 33% in the Company's equity share capital, the EPS has improved during the quarter. This improvement reflects the fact that the growth in profitability has more than outpaced the increase in the equity share base, demonstrating stronger earnings generation despite the dilution arising from the preferential allotment.
5	The results are also available on the webiste of the Company www.concorddrugs.in

Concord Drugs Limited * Hyderabad *

By Order of the Board
For Concord Drugs Limited

Nagi Reddy Seelam
Managing Director
DIN: 01764665

Place: Hyderabad
Date: 12.11.2026

Concord Drugs Limited
Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana

STATEMENT OF UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE SIX MONTHS ENDED 30th September 2026

[Rs. in Lakhs]

	Particulars	Quarterly ended			Half Year ended		Year Ended
		30-Sep-26 (Un Audited)	30-Jun-26 (Un Audited)	30-Sep-25 (Un Audited)	30-Sep-26 (Un Audited)	30-Sep-25 (Un Audited)	31-Mar-26 (Audited)
I	**Revenue from Operations**						
	a. Net sales from Operations	2,075.33	2,093.88	1,027.61	4,169.21	2,388.25	7,873.68
	b. Other Operating Income	5.61	0.82	0.24	6.43	0.24	3.44
II	**Other Income**						
III	**Total Revenue (I+II)**	**2,080.95**	**2,094.70**	**1,027.85**	**4,175.65**	**2,388.49**	**7,877.13**
IV	**Expenses**						
	a.Cost of Material Consumed	1,703.71	1,652.38	776.35	3,356.09	1,857.57	6,700.61
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-64.50	38.98	-4.51	-25.52	56.13	63.98
	c. Employees Benefit Expenses	156.27	125.58	109.46	281.85	198.06	497.05
	d. Finance Costs	55.67	39.61	48.81	95.28	97.82	171.37
	e. Depreciation and Amortisation expense	35.78	34.93	33.94	70.71	70.72	136.67
	f. Other expenses	43.40	48.73	36.69	92.13	65.24	160.13
	Total Expenses	**1,930.32**	**1,940.21**	**1,000.74**	**3,870.53**	**2,345.54**	**7,729.81**
	Profit/ (Loss) before Exceptional item and tax (III-IV)	**150.63**	**154.49**	**27.11**	**305.12**	**42.95**	**147.32**
V	**Exceptional Items**	-	-	-	-	-	-
VI	**Profit/ (Loss) before tax (V-VI)**	150.63	154.49	27.11	305.12	42.95	147.32
VII	**Tax Expense:**	**40.89**	**43.09**	**7.89**	**83.98**	**11.95**	**41.82**
VIII	a. Current tax	41.52	44.15	7.83	85.67	13.17	41.98
0	b. Deferred tax charge/credit	-0.63	-1.06	0.06	-1.69	-1.22	-0.16
IX	**Profit/ (Loss) for the period (VII-VIII)**	**109.74**	**111.40**	**19.22**	**221.14**	**31.00**	**105.50**
X	**Other Comprehensive Income**	-			-	-	-
	Items that will not be reclassified to profit or loss	-			-	-	-
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	109.74	111.40	19.22	221.14	31.00	105.50
XI	**Paid up Capital** (Face value of the share- Rs. 10 each)	1,317.50	1,317.50	1,000.00	1,317.50	1,000.00	1,317.50
	Other Equity	3,754.68	3,645.12	2,441.89	3,754.68	2,441.89	3,533.89
XII	**Earnings per share (of Rs. 10 each)(in Rupees)**						
XIII	a. Basic (in Rs)	0.83	0.85	0.19	1.68	0.31	0.95
	b. Diluted (in Rs)	0.83	0.85	0.19	1.68	0.31	0.95

Notes:

1	The finnacial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
2	The above Consolidated financial results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 12.11.2026
3	Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.
4	The Earnings Per Share (EPS) for the quarter ended is not strictly comparable on a Quarter-on-Quarter (QoQ) and Year-on-Year (YoY) basis, as the weighted average number of equity shares outstanding increased during quarter ended 31.03.2026 pursuant to the allotment of 31,75,000 equity shares at ₹36.50 per share through a preferential issue. Notwithstanding the increase of over 33% in the Company's equity share capital, the EPS has improved during the quarter. This improvement reflects the fact that the growth in profitability has more than outpaced the increase in the equity share base, demonstrating stronger earnings generation despite the dilution arising from the preferential allotment.
5	The results are also available on the webiste of the Company www.concorddrugs.in

Concord Drugs Limited * Hyderabad *

By Order of the Board
For Concord Drugs Limited

Nagi Reddy Seelam
Managing Director
DIN: 01764665

Place: Hyderabad
Date: 12.11.2026

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement Un Audited Consolidated Cash flow for the Six Months ended 30.09.2026 **Amount in Lakhs**

Particulars	September 30, 2026		March 31, 2026	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		305.12		147.32
Adjustments for :				
Profit on sale of ASSets				
Depreciation and amortisation expense	70.71		136.67	
Finance costs	95.28		171.37	
Interest income	-6.43		-3.44	
Provision for Gratutiy				
		159.55		**304.59**
Operating profit before working capital changes		**464.67**		**451.91**
Changes in working capital: (Refer Note 40)				
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables	-1,568.86		-1,077.67	
Loans and Advances	-102.55		0.00	
Other Non Current assets	-44.58		258.63	
Inventories	109.95		-24.73	
Other Current assets	-593.45		-108.38	
Other bank balances	1.30		-36.78	
Other Current financial Assets	-31.10		8.34	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	1,142.52		-57.35	
Borrowings				
Other current financial liabilities	-90.88		-114.24	
Other current liabilities	-21.62		44.88	
Current tax liabilities, net	85.60		20.76	
Provisions	-		-	
Deferred tax on amalgamation				
Cash generated from operations		**-648.99**		**-634.64**
Net income tax paid		-85.67		-41.98
Net cash flow from operating activities (A)		**-734.67**		**-676.61**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-44.84		-116.69	
Proceeds from maturiy of fixed deposits	-		-	
Investment				
- Subsidiaries	-		-	
- Others	6.43		3.44	
Net cash (used in) / flow from investing activities (B)		**-38.40**		**-113.25**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	-		317.50	
Finance costs	-95.28		-171.37	
Repayment of Borrowings	320.31		48.15	
Repayment of short term Borrowings	549.25		-407.49	
Govt Grants				
Other equity Adjustment	-		1,018.79	
Net cash flow (used in) financing activities (C)		774.28		805.58
Net (decrease) in Cash and cash equivalents (A+B+C)		1.21		15.72
Cash and cash equivalents at the beginning of the year		27.81		12.09
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		29.03		27.81
* Comprises:				
Balances with Banks		0.09		0.09
Others		28.94		27.72
		29.03		27.81

By Order of the Board
For Concord Drugs Limited

Concord Drugs Limited * Hyderabad *

S. N. Reddy

Nagi Reddy Seelam
Managing Director
DIN:01764665

Place:Hyderabad
Date:12.11.2026

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Statement of Un Audited Standalone Cash flow for the Six Months ended 30.09.2026 Rs in Lakhs

Particulars	September 30, 2026		March 31, 2026	
A. CASH FLOW FROM OPERATING ACTIVITIES				
Profit Before Tax		304.65		144.86
Adjustments for :				
Profit on sale of ASSets				
Depreciation and amortisation expense	70.36		135.72	
Finance costs	86.62			
on Bank Loan		-	138.13	-
on Bank Chaarges			7.78	
Interest income	-6.43		-3.44	
Provision for Gratutiy				
		150.54		**278.19**
Operating profit before working capital changes		**455.19**		**423.05**
Changes in working capital: (Refer Note 40)				
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables	-1,619.41		-1,545.55	
Loans and Advances	-102.55		-	
Other Non Current assets	-44.58		258.63	
Inventories	117.70		77.63	
Other Current assets	-592.13		-93.06	
Other bank balances	1.30		-36.78	
Other Current financial Assets	-31.10		8.34	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	1,179.61		259.63	
Borrowings				
Other current financial liabilities	-90.88		-114.24	
Other current liabilities	-21.69		44.72	
Current tax liabilities, net	85.60		22.35	
Provisions	-		-	
Deferred tax on amalgamation				
Cash generated from operations		**-662.94**		**-695.29**
Net income tax paid		-85.60		-41.34
Net cash flow from operating activities (A)		**-748.54**		**-736.63**
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-44.84		-116.69	
Proceeds from maturiy of fixed deposits				
Investment			3.44	
- Subsidiaries	-			
- Others	6.43		-	
Net cash (used in) / flow from investing activities (B)		**-38.40**		**-113.25**
C. CASH FLOW FROM FINANCING ACTIVITIES				
Proceeds from issue of equity shares	-		317.50	
Finance costs	-86.62			
on Bnak Loan			-138.13	
on Bank charges			-7.78	
Repayment of Borrowings	320.31		49.79	
Repayment of short term Borrowings	553.33		-374.74	
Govt Grants	-		-	
Other equity Adjustment	-		1,018.79	
Net cash flow (used in) financing activities (C)		787.02		865.44
Net (decrease) in Cash and cash equivalents (A+B+C)		0.09		15.56
Cash and cash equivalents at the beginning of the year		27.10		11.54
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-		-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		27.18		27.10
* Comprises:				
Balances with Banks		0.09		0.09
Others		27.09		27.01
		27.18		**27.10**

By Order of the Board
For Concord Drugs Limited

Concord Drugs Limited * Hyderabad *

Nagi Reddy Seelam
Managing Director
DIN:01764665

Place:Hyderabad
Date:12.11.2026

PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033
E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2026, and the year to date results for the period 1 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six-month period ended 30 September 2026 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.

2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India.


   A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and

PUNDARIKASHYAM & ASSOCIATES HYDERABAD Chartered Accountants

other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement,prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.



B.Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN: 26205125WBQZZ08276.

Place: Hyderabad
Date: 12-11-2026.

PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

1-8-435/436, 2nd Floor, Durga Towers, Beside Rasoolpura Metro Station, Begumpet, Hyderabad, Telangana - 500016. Cell : 9440464339, Ph : 040-35175033
E-mail : info@pkas.in / infoong@pkas.in

GSTIN : 36AAJFP6218J1ZY

Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of Consolidated unaudited financial results ('the Statement') of Concord Drugs Limited ('the group company') for the quarter ended 30 September 2026, and the year to date results for the period 1 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six-month period ended 30 September 2026 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.

2. The statement, which is the responsibility of the Group Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34,Interim Financial Reporting('Ind AS 34'),prescribed under section 133 of the Companies Act, 2013 ('the act'),SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'),and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

PUNDARIKASHYAM & ASSOCIATES ★ HYDERABAD ★ Chartered Accountants

4. The Statement includes the results of the following entities:
   Proton Remedies Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement,prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The accompanying Statement includes the unaudited financial results and other financial information, in respect of one subsidiary, whose unaudited financial results include total revenues of Rs 74.83 lakhs, total net profit after tax of Rs.0.34 lakhs, for the half year ended Sep 30, 2026, as considered in the Statement which have been reviewed by their respective independent auditors. The independent auditor's reports on unaudited interim financial results and other financial information of these entity have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement in respect of matters stated in para above is not modified with respect to our reliance on the work done and the reports of the other auditor.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.

PUNDARIKASHYAM & ASSOCIATES ★ HYDERABAD ★ Chartered Accountants

B. Surya Prakasa Rao
(Partner)
MNo: 205125
UDIN: 26205125CKNGOK3330.

Place: Hyderabad
Date: 12-11-2026.